Central Nervous System Tumors clinical trials

Explore recruiting central nervous system tumors clinical trials.

Recruiting central nervous system tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Central Nervous System Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Single-arm, multicenter Phase I/Ib study of avelumab + lenvatinib in children with primary CNS tumors

France, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

(20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

France, Netherlands, Czechia, Italy, Germany, Sweden +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory central nervous system tumors

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Denmark, France, Germany, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II trial aiming to assess the safety and clinical activity of Tarlatamab in combination with metronomic Temozolomide in adolescents and adults’ patients with high grade brain tumors

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

France, Italy, Spain, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Central Nervous System Tumors trials by city

Central Nervous System Tumors in Toronto Central Nervous System Tumors in Vancouver Central Nervous System Tumors in Montreal Central Nervous System Tumors in Calgary Central Nervous System Tumors in Edmonton Central Nervous System Tumors in Ottawa Central Nervous System Tumors in Winnipeg Central Nervous System Tumors in Quebec City Central Nervous System Tumors in Hamilton Central Nervous System Tumors in Kitchener Central Nervous System Tumors in London Central Nervous System Tumors in Halifax Central Nervous System Tumors in New York Central Nervous System Tumors in Los Angeles Central Nervous System Tumors in Chicago Central Nervous System Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease